T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation.

NCT02849886 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped not enough recruitment because of new therapeutic alternatives

Conditions

Graft Versus Host Disease
Hematological Malignancies

Interventions

DRUG: T lymphocytes iCASP9 ΔCD19
DRUG: Dimerizer drug AP1903

Sponsor

Centre Hospitalier Universitaire de Besancon

Collaborators

[object Object]
[object Object]